Literature DB >> 7088510

The onset and evolution of glaucomatous visual field defects.

W M Hart, B Becker.   

Abstract

Long-term follow-up was recorded on the visual fields of 251 patients with chronic open-angle glaucoma and 826 patients with ocular hypertension. Observation periods exceeded ten years for 73 patients with manifest glaucoma. Initial glaucomatous defects appeared in 98 eyes of 72 patients while under continuous observation. Initial defects were characteristically shallow and were located most commonly in the superior Bjerrum region adjacent to the blind spot. Three-dimensional (contiguous area) static perimetry provided superior resolution in detecting and characterizing the full extent of such shallow defects. The chronologic course of initial defects defects was marked in 22 of the 98 eyes by a phenomenon of a transiently appearing defect. Disappearance and reappearance of transient defects did not occur synchronously with short-term fluctuations in intraocular pressure. Ten-year follow-up of 63 eyes with manifest glaucomatous defects showed a high incidence (73%) of progression to dense involvement of the originally affected altitudinal hemifield. All eyes were treated continuously, but visual field loss occurred in spite of only marginally elevated levels of intraocular pressure.

Entities:  

Mesh:

Year:  1982        PMID: 7088510     DOI: 10.1016/s0161-6420(82)34798-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  51 in total

Review 1.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  Blood flow per unit retinal nerve fibre tissue volume is lower in the human inferior retina.

Authors:  A Harris; Y Ishii; H S Chung; C P Jonescu-Cuypers; L J McCranor; L Kagemann; H J Garzozi
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

3.  Intraocular pressure-related pattern of optic disc cupping in adult glaucoma patients.

Authors:  D H Shin; M K Lee; K S Briggs; C Kim; J H Zeiter; B McCarty
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

4.  Relationships between visual field sensitivity and spectral absorption properties of the neuroretinal rim in glaucoma by multispectral imaging.

Authors:  Jonathan Denniss; Ingo Schiessl; Vincent Nourrit; Cecilia H Fenerty; Ramesh Gautam; David B Henson
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

5.  New superior-inferior visual field asymmetry indices for detecting POAG and their agreement with the glaucoma hemifield test.

Authors:  N Ghazali; T Aslam; D B Henson
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

6.  Full threshold versus quantification of defects for visual field testing in glaucoma.

Authors:  W C Stewart; M B Shields; A R Ollie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

7.  Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study.

Authors:  John L Keltner; Chris A Johnson; Richard A Levine; Juanjuan Fan; Kimberly E Cello; Michael A Kass; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2005-09

8.  Pupillary evaluation of retinal asymmetry: development and initial testing of a technique.

Authors:  Yanjun Chen; Harry J Wyatt; William H Swanson
Journal:  Vision Res       Date:  2005-09       Impact factor: 1.886

9.  Imaging Glaucomatous Damage Across the Temporal Raphe.

Authors:  Gang Huang; Ting Luo; Thomas J Gast; Stephen A Burns; Victor E Malinovsky; William H Swanson
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

10.  Diabetes in primary open-angle glaucoma patients with inferior visual field defects.

Authors:  J H Zeiter; D H Shin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-04       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.